Peter Carr

Lantern Pharma, Inc. is a clinical-stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data, and precision oncology trials. Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.